Cancer immunotherapy with antibodies targeting immune checkpoints, such as programmed cell death protein 1 (PD-1), shows encouraging results, but reliable biomarkers predicting response to this costly and potentially toxic treatment approach are still lacking. To explore an immune signature predictive for response, we performed liquid biopsy immunoprofiling in 18 cancer patients undergoing PD-1 inhibition before and shortly after initiation of treatment by multicolor flow cytometry and nextgeneration T-and B-cell immunosequencing (TCRß/IGH). Findings were correlated with clinical outcomes. We found almost complete saturation of surface PD-1 on all T-cell subsets after the first dose of the antibody. Both T-and B-cell compartments quantitatively expanded during treatment. These expansions were mainly driven by an increase in the activated T-cell compartments, as well as of na€ ıve B-and plasma cells. Deep immunosequencing revealed a clear diversification pattern of the clonal T-cell space indicative of antigenic selection in 47% of patients, while the remaining patients showed stable repertoires. 43% of the patients with a diversification pattern showed disease control in response to the PD-1 inhibitor. No disease stabilizations were observed without clonal T-cell space diversification. Our data show for the first time a clear impact of PD-1 targeting not only on circulating T-cells, but also on B-lineage cells, shedding light on the complexity of the anti-tumor immune response. Liquid biopsy T-cell next-generation immunosequencing should be prospectively evaluated as part of a composite response prediction biomarker panel in the context of clinical studies.
Introduction
Programmed cell death protein 1 (PD-1) is a receptor expressed by activated T-cells which binds to PD ligand 1 (PD-L1) on cancer cells and other cells in the tumor microenvironment. 1 Physiologically, PD-L1 is upregulated to prevent tissue damage in case of inflammation. In the tumor microenvironment, upregulation of PD-L1 leads to suppression of tumor immunity and inhibition of its interaction with PD-1 may rescue the disabled immune response against cancer cells. PD-1 targeting antibodies have been approved for the treatment of malignant melanoma, lung and renal cancer based on impressive clinical activity in patients with advanced disease and more indications are likely to follow in the coming years. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Despite considerable responses including long-term remissions in some patients, the majority of patients across the different disease entities does not benefit from this costly treatment approach. New biomarkers before or at an early time point in the course of treatment are therefore an unmet clinical need to identify patients with a low or high chance of deriving benefit from these drugs. Although high expression of PD-L1 by immunohistochemistry enriches for response, low expression does not preclude clinical benefit. 4, 11, [14] [15] [16] [17] In part, these inconsistent correlations may be related to the selection of antibody, target cell and cut off value, that may be further refined in the future. 15 However, PD-L1 expression certainly has to be viewed within the context of other variables -potentially as a composite biomarker -when attempting to reliably predict treatment response to anti-PD therapy. 18 A growing body of evidence supports the hypothesis that tumor mutational load may help to predict clinical benefit from immune checkpoint inhibitors. Exome sequencing of tumors from patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab revealed that a high burden of somatic mutations or neoantigens, a molecular signature characteristic of tobacco carcinogen-related mutagenesis and certain DNA repair mutations correlated with clinical efficacy. 19 In patients with a large number of somatic mutations due to mismatch repair deficient cancers, mismatch repair status predicted clinical benefit from pembrolizumab. 20 Moreover, some studies suggested certain patterns of tumor-infiltrating lymphocytes (TiLs) as potentially predictive of response to immune checkpoint inhibition. Tumeh et al. analyzed samples from patients with melanoma during anti-PD-1 therapies and showed that pretreatment samples from responding patients showed higher numbers of CD81, PD1 and PD-L1 expressing cells at the invasive tumor margin, and a more clonal T-cell environment. 21 Such immune environment profiling mainly relies on pre-treatment tumor tissue and may not be easily used to study dynamics over treatment, which would require repetitive tumor sampling. For dynamic measurements, peripheral blood immune monitoring is very attractive given the easy access in clinical practice. This concept (for which first evidence is available 22 ) implies that the circulating immune cells somewhat reflect or overlap with the tumor's TiL repertoire. This may allow using peripheral blood as liquid biopsy that provides a representative picture of the tumor-resident anti-tumor lymphocytes. Earlier studies have addressed peripheral blood immunoprofiling in the context of anti-CTLA4 antibodies. [23] [24] [25] [26] CTLA-4 targeting quite uniformly induced T-cell repertoire evolution and diversification, which could -however -not be correlated to clinical responses. A study by Cha et al. 26 suggested that improved clinical outcomes were associated with the maintenance of high frequency T-cell receptor clonotypes during CTLA-4 targeting which could potentially be used as a predictive biomarker in this setting.
Despite the large amount of clinical studies, peripheral blood immune environments and their dynamics are largely unexplored in the context of PD-1 targeting thus far. Here, we analyzed pre-and post-treatment peripheral blood immune signatures in a monocenter "real life" cohort of 18 patients treated with nivolumab or pembrolizumab by multicolor flow cytometry and next-generation immunosequencing. We found a clear diversification pattern of the T-cell repertoires in about half of the patients by this liquid biopsy approach. About half of the patients showing this pattern experienced disease stabilization in the course of treatment. Early T-cell repertoire diversification upon PD-1 inhibition should therefore be prospectively evaluated as predictive biomarker in future studies.
Material and Methods

General lab operation
These studies were conducted in a laboratory conducting exploratory research (NGS) and a laboratory operating as diagnostic unit for hematological malignancies and immunological diagnostics according to local standard operating procedures and as accredited by INSTAND e.V., WHO Collaborating Centre for Quality Assurance and Standardization in Laboratory Medicine (flow cytometry). The study was performed using investigative protocols (NGS) as well as standard operating protocols (flow cytometry). All experiments were conducted in accordance with MIATA guidelines as specified below.
Patient characteristics
Eighteen patients with metastatic cancer were analyzed in our study (Table 1 ). All patients were treated with the PD-1 targeting antibodies nivolumab or pembrolizumab after progression of disease on previous therapy. Prior therapies included surgery, radiation and chemotherapy, which often consisted of several lines. PD-L1 diagnostic testing was performed on tumor tissue sections using the PD-L1 antibody clone E1L3N (Cell Signaling Technology, Cambridge, UK). Immune checkpoint inhibition was initiated either within the licensed indication or off-label based on published data. 20, 27, 28 Analysis was done on peripheral blood samples
What's new?
Blocking immune-checkpoint receptors on T cells may enhance the immune response against tumor cells. Clinical results for antibodies that target these receptors have been encouraging, but the treatments are costly and potentially toxic. Biomarkers that help predict response to treatment are thus urgently needed. In our study using blood from patients undergoing anti-PD1 immunotherapy, the authors identified specific "TCRß immune signatures" that correlated with a good response to therapy about half the time. These expression signatures may thus represent a promising predictive biomarker and should be tested further. All patients received nivolumab or pembrolizumab every 2 or 3 weeks, respectively, and blood samples for NGS and flow cytometry were taken prior to treatment initiation and before the second antibody dose; in Patient 16 the post-treatment sample was taken after the third antibody dose, since prior time points were not evaluable. EGJ, cancer of esophagogastric junction; NSCLC, non-small cell lung cancer; CC, Cholangiocarcinoma; GC, gastric cancer; RCC, renal cell carcinoma; LN, lymph node; Nivo, nivolumab; Pembro, pembrolizumab; PR, partial response; SD, stable disease; MR, mixed response; PD, progressive disease; 5FU/F, 5-flourouracil; Axi, axitinib; Bev, bevacicumab; Cap, capecitabine; Carbo, carboplatin; Cis, cisplatin; Doce, docetaxel; Erlo, erlotinib; Gem, gemcitabine; IFN, interferon alpha; Ipi, ipilimumab; Iri, irinotecan; L, leuocovorine; MitoC, mitomycin C; Ox/O, oxaliplatin; Pacli, paclitaxel; Pani, panitumumab; Pazo, pazopanib; Pem, pemetrexed; Pert, pertuzumab; Rad, radiation; Ramu, ramucirumab; RCx, radiochemotherapy; Reg, regorafenib; Suni, sunitinib; TACE, trancatheter arterial chemoembolization; Tras, trastuzumab; Vacc, vaccination; Vino, vinorelbine; 1 indicates ongoing therapy; 2 Months from first diagnosis; PD-L1 staining was performed using the PD-L1 antibody clone E1L3N (Cell Signaling Technology, Cambridge, UK); n.e., not evaluable.
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before the first dose of the antibody and after 2-6 weeks of treatment. The trial has been performed in accordance with the Helsinki declaration of 1975 and approved by the Landes€ arztekammer Hamburg. Informed consent was obtained from all patients.
Isolation of peripheral blood cells
Donor information is provided in Table 1 of the article. Peripheral blood was collected in heparin tubes at room temperature and subjected to erythrocyte lysis using a standard lysis buffer (ammonium chloride 8.29 g/l, EDTA 0.372 g/l, potassium hydrogen carbonate 1 g/l) for direct utilization in flow cytometry experiments and ficoll gradient centrifugation for isolation of peripheral blood mononuclear cells (PBMCs) which were subsequently frozen in freezing media (90% fetal bovine serum (Biochrom, VWR, Darmstadt, Germany), 10% Dimethyl sulfoxide (Sigma-Aldrich, Taufkirchen, Germany) for later DNA preparation and NGS. PBMCs were frozen at a cell count of 106-107 cells/ml in 1.2 ml cryovials (Carl Roth, Karlsruhe, Germany) using Mr. Frosty (Nalgene, Sigma Aldrich) following the manufacturer's instructions. After overnight incubation cells were stored in a 2808C freezer until further use. Freezing and thawing resulted in 60-90% viability of the PBMCs as assessed by trypan blue staining on the cell counter Vi-CELL TM XR (Beckmann Coulter, Krefeld, Germany). Previously frozen cells were only used for DNA preparation. Flow cytometry assays were performed with freshly isolated cells.
Multicolor flow cytometry
Flow cytometry was performed using an 8-color flow cytometry panel (Supplementary Table S1 ) within 2 hr of blood collection. Measurements were performed on a Navios flow cytometer (Beckman Coulter, Krefeld, Germany). The gating strategy has been previously described including raw data sets for this flow cytometry immunoprofiling approach. 29 
PD-1 antibody competition assay
The flow cytometry anti-PD-1 detection antibody PD1.3/BD was used for competition assays on primary patient T-cells preincubated with increasing concentrations of pembrolizumab (0, 0.1, 1, 10, 100 and 1,000 mg/ml).
Isolation of genomic DNA
Genomic DNA was isolated from >10 6 fresh frozen PBMCs (one vial per patient and time point) using Gen Elute mammalian genomic DNA miniprep kit (Sigma-Aldrich) according to the supplier's suggestions.
T-cell receptor beta (TCRß) and immunoglobulin heavy chain (IGH) repertoire amplification for Illumina targeted next-generation sequencing (NGS)
The IGH and TCRß genes containing the entire V ß , D ß and J ß segments were amplified with BIOMED2-FR1 (IGH), -TCRß-A and -B primer pools. 30 Using genomic DNA as template, the amplicons were tagged with Illumina adapters and indices in two consecutive PCR reactions (schematically shown in Supplementary Figure S1 ). In the first PCR, inner primers annealing within either the IGH or TCRß loci (shown as black arrows) containing Illumina-compatible adapters (green) for later hybridization of amplicons to the Illumina flow cell and sequencing were used. In the second PCR, the Illumina adapter sequences (blue) were extended and a barcode consisting of 7 nucleotides (red), which allowed matching of each sequence during the later data analysis to a certain patient and time point, was added using outer primers. All primers (purchased from Metabion, Martinsried, Germany) used in our study are summarized in Supplementary Table S2 . Phusion HS II (Thermo Fisher Scientific, Inc., Darmstadt, Germany) was used for all PCRs. Both PCR reactions were size separated by agarose gel electrophoresis and amplicons with the expected size were purified using the NucleoSpin V R Gel and PCR Clean-up kit (Macherey-Nagel, D€ uren, Germany). Before being used for NGS, the concentration of the amplicons was determined on Qubit (QIAGEN, Hilden, Germany) and amplicon purity was controlled on an Agilent 2100 Bioanalyzer (Agilent technologies, B€ oblingen, Germany).
Illumina NGS and data analysis
NGS was performed using an Illumina MiSeq sequencer [500 or 600 cycle single indexed, paired-end runs (V2 or V3 chemistry)]. The adapter-ligated PhiX library was used as an internal control for Illumina sequencing runs. Demultiplexing and FastQ formatted data output was generated by the MiSeq reporter. Analysis of IGH and TCRß data was performed on our in-house pipeline, which relies on the MiXCR analysis tool.
31,32
Diversity indices
Differences in TCRß CDR3 clonotype distributions were studied using Shannon-Wiener and inverse Simpson diversity indices using the formulas shown in Supplementary Figure  S2 . 33, 34 Shannon-Wiener is a diversity index of first order, inverse Simpson of second order. Indices with an order of >1 are disproportionately sensitive to the most common species/clonotypes, while all others are more sensitive to the rare species/clonotypes. 34 Indices were calculated for each sample and time point to be able to compare immune repertoire diversity before and after initiation of treatment. TCRß diversification was assumed, when both diversity indices increased after the first dose of the antibody.
Statistical analysis
Statistical significance of the data either resulting from flow cytometry or NGS was calculated using Student's t-test (paired samples). Correlations between clinical response and TCRß diversification was studied using v 2 statistics. All statistical analyses have been calculated using excel (Microsoft) or GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA).
Results
Clinical outcome of patients treated with PD-1 inhibiting antibodies
Three of the 18 patients treated with PD-1-inhibiting antibodies achieved disease control. These three patients included one male melanoma patient (Patient 2), one female patient with gastric cancer (Patient 9) and one female patient with non-squamous NSCLC (Patient 16). Patient 2 has ongoing stable disease of lymph node and pulmonary melanoma metastases with nivolumab for >10 months. Patient 9 achieved ongoing partial remission of cervical and abdominal lymph node metastases with stable bone lesions for now >7 months. Patient 16 has ongoing stable disease of primary tumor and hepatic metastasis with clinical stabilization and normalization of elevated LDH. Patient characteristics and outcomes are summarized in Table 1 .
Flow cytometry profiling of circulating leukocyte subsets during treatment
Circulating leukocyte subsets were profiled with a special focus on T-and B-cell maturation, activation and inhibition using the antibody panel shown in Supplementary Table S1 . Exemplary flow cytometry plots as well as the gating strategy are shown in Supplementary Figure S3 . Circulating T-cells exhibited a mean percentage of 15.5% PD-11/CD41 T-cells and 26.6% PD-11/CD81 T-cells before treatment. After the first dose of the PD-1 antibody, PD-1 positivity was reduced to a mean percentage of 0.4% and 1.2% of PD-11/CD41 and PD-11/CD81 T-cells, respectively (Figs. 1a and 1b) . This reduction in PD-1 positivity reflected the saturation of cell surface PD-1 with the respective therapeutic antibody that competes with the flow cytometry detection antibody for its binding site ( Supplementary Fig. S4 ). When comparing the pre-treatment time point with an early time point after initiation of treatment (2-6 weeks), we observed significant shifts in the T-and B-cell compartments, while no systematic effects could be observed for other compartments, such as granulocytes, monocytes, NK or NKT-cells. Global T-and Bcell compartments quantitatively expanded during treatment (Figs. 2a and 2b ). There were no significant differences in the numbers of regulatory T-cells (Treg) before and after initiation of PD-1 directed checkpoint inhibition (Figs. 2c and 2d and Supplementary Figs. S5A and S5B ). In terms of T-cell maturation, the distribution of central memory and effector memory T-cells was relatively stable over time (Supplementary Figs. S5C-S5F). Since absolute T-cell numbers increased, this also resulted in a significant absolute increase in the most abundant subsets, such as central memory CD41/ CD81 cells and effector memory CD81 cells (Figs. 2eh) . Moreover, we found a relative and absolute increase in the activated CD41 and CD81 T-cell compartments (Figs. 2il and Supplementary Figs. S5G-S5J ). Overall our flow cytometry T-cell immunoprofiling suggested that PD-1 inhibition globally resulted in T-cell expansion (without significant maturation shifts) as well as a significant increase in T-cell activation.
Of the B-lineage, na€ ıve B-cells and the subset of circulating plasma cells expanded significantly, suggesting a potentially indirect effect on the PD-1-negative B-cell lineage by the checkpoint inhibitor (Figs. 2mo) .
NGS of T-cell immune repertoires
The number of TCRß reads ranged around 10,000 (mean number of reads: 9,920) per liquid biopsy and time point; the number of individual TCRß clonotypes around 2,000 (mean number of clonotypes: 2,138). We found a statistically significant diversity increase in the circulating T-cell repertoire when comparing blood samples taken prior to versus 2-6 weeks after initiation of treatment as quantified by the two common Shannon-Wiener and inverse Simpson diversity indices ( Supplementary Fig. S2 ). In individual patients, T-cell Flow cytometry stainings were performed on freshly isolated peripheral blood cells and analyzed on a Navios flow cytometer. Note that patients 12-14 died shortly after the first application of the antibody. Therefore, no matched pre-and post-therapeutic samples were available for analysis. In patients 11 and 17, one of the flow cytometry results was not evaluable. PD-1: Programmed cell death protein 1. Statistical analysis was performed using Student's t-test.
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TCR diversification in checkpoint inhibition
clonal space diversifications indicative of antigenic selection were assumed when both indices increased upon initiation of treatment. According to this definition, NGS of the circulating T-cell repertoire revealed a clear diversification pattern of the clonal T-cell space in 47% of patients, while the remaining patients showed stable repertoires (Fig. 3) . Diversification was visualized by the percentage of smaller T-cell clones occupying the peripheral clonal T-cell space. Figure 4 shows the distribution of the peripheral blood TCRß rearrangements of two representative cases with (Patient 16) or without (Patient 18) TCRß diversification. No consistent shifts in TCRß-VJ gene usage were discernable prior to versus 2-6 weeks after initiation of treatment (Supplementary Fig. S6 ). T-cell diversification did not correlate with T-cell expansion defined as >50% increase in total T-cell numbers after initiation of checkpoint inhibition as evidenced by flow cytometry (v 2 p 5 0.13).
NGS of B-cell immune repertoires
The number of IGH reads ranged around 15,000 (mean number of reads: 16,534) per liquid biopsy and time point; the number of individual IGH clonotypes around 1,000 (mean number of clonotypes: 1,306). The rate of IGH somatic hypermutation in circulating B-lineage cells was essentially stable in pre-and posttherapeutic liquid biopsies reflecting the expansion of both na€ ıve B-and plasma cell compartments ( Supplementary Fig. S7 ). Likewise, no consistent shifts in IGH-VJ gene usage were discernable pre-and post-treatment ( Supplementary Fig. S8 ).
Correlation with clinical courses
Neither pre-treatment leukocyte subset distribution, nor pretreatment TCRß/IGH diversity or IGH somatic hypermutation appeared to correlate with response to treatment in this small cohort. When looking at the dynamics across treatment, we found a quite uniform response pattern to immune checkpoint inhibition in terms of leukocyte subset shifts. In contrast, the TCRß diversification pattern was clearly restricted to a subset of patients. When correlating TCRß diversification with clinical outcome, we found that this pattern was statistically associated with disease control in our cohort (v 2 p 5 0.038; Fig. 5 ) despite the very limited size of 
Tumor Immunology and Microenvironment
the cohort. 43% of the patients with a TCRß diversification pattern showed disease stabilization (PR or SD) in response to the PD-1 inhibitor. While patients without T-cell clonal space diversification received a mean of only four PD-1 antibody applications, patients with T-cell clonal space diversification received a mean of nine antibody applications. No disease stabilizations were observed without T-cell clonal space diversification.
Discussion
Anti-PD-1 antibodies blocking inhibitory pathways to promote effective immune-mediated tumor attack are currently on the rise. However, reliable predictive markers to assess which patients are likely to benefit from this treatment approach are lacking. In addition to molecular testing of the tumor itself -e.g. for PD-L1 expression or mutational loadhost immune profiles may be exploited as response prediction biomarker enabling rational patient selection. Previous studies suggest that patients responding to PD-1 inhibitors are characterized by a distinct pattern of immune cell infiltration at the tumor site 21 but little is known about the immune cell repertoire in the peripheral blood and how accurately this repertoire reflects the immune response at the tumor site. 25, 26 Recent studies suggest that the antigen-specificity of tumor-reactive T-cells in the peripheral blood very much resembles that of the T-cells in the tumor, indicating that such a liquid biopsy may obviate the need to obtain fresh tumor tissue. 22, 35 Two blood-based studies on T-cell repertoire evolution have already been conducted in patients treated with anti-CTLA-4 antibodies. Both studies found that immunotherapy diversified the T-cell pool in the majority of patients. Yet, no diversification differences were noted between clinical responders and non-responders. Improved survival appeared, however, to be associated with maintenance of high-frequency clonotypes during treatment. 26 Here, we obtained a comprehensive blood-based immune signature before and early in the course of PD-1 directed immune checkpoint inhibition in a "real life" cohort of 18 patients with different cancers. Our multicolor flow cytometry results show that central memory T-cells as well as activated and effector memory CD81 T-cells increased during treatment with PD-1 inhibitors. Interestingly, na€ ıve B-cells and the small subset of circulating plasma cells also expanded significantly. These effects were relatively consistent within the cohort and lacked correlation with response. Next-generation immunosequencing of the peripheral T-cell repertoire of these patients, however, revealed a distinct diversification pattern indicative of immune response in only a subset of patients. Of these, 43% showed disease control, while none of the patients without Tcell diversification clinically stabilized (v 2 p 5 0.038). This result clearly differs from previous findings with antibodies against CTLA-4, a checkpoint that is involved in the early priming phase of the immune response, showing quite universal T-cell diversification irrespective of clinical response. Despite the generally low rate of disease stabilizations in our cohort, this finding is interesting and should clearly trigger further prospective studies of T-cell diversification as early response predictor for PD-1 immunotherapy. In addition to guiding clinical decisions on treatment continuation at an early time point, this marker could potentially also help in the identification of patients with pseudoprogressions. Clinical trials suggest that a small percentage of patients treated with PD-1 inhibitors have an immunerelated response pattern with early paradoxical pseudoincreases in total tumor burden followed by delayed clinical response at later clinical assessments. These pseudoprogressions are not captured by RECIST criteria and pose a challenge in clinical practice. 36 If the T-cell diversification pattern proves to be predictive for response, patients with such a signature and putative pseudoprogressions could more permissively be held on treatment than patients without evidence for T-cell diversification. From a biological perspective, the expansion of B-lineage cells upon immune checkpoint inhibition is remarkable. It indicates that immunotherapy with anti-PD-1 antibodies alters not only the T-but also the B-cell pool. Since Blineage cells usually do not express PD-1 (except for tissueresiding PD-111 regulatory B-cells with tumor promoting properties 37 ), our finding of expanded B-lineage cells may indicate that antigen-dependent maturation of B-cells to plasma cells or expansion of preexisting plasma cells following treatment with anti-PD-1 antibodies occurs via an indirect mechanism, for example T-cell mediated. We cannot exclude, however, that the PD-1 antibody directly inhibits tissueresiding or lymphoid organ B-cells and thereby promotes anti-tumor immunity.
One of the limitations of our patient cohort is clearly the limited size and low overall disease control rate that precludes more extensive clinical correlations. Twelve of the 18 patients in this cohort progressed very early in the course of treatment after a mean of only two antibody infusions. The majority of patients with T-cell diversification showing no disease stabilization also discontinued treatment (and died) very early in the course. Therefore, the short life span of these patients may have prevented any potential immune effects to translate into a clinical benefit, since the median time from treatment initiation until clinical response ranges around 2-3 months. 11, 38 The apparently suboptimal selection process for immune checkpoint inhibition in this "real-life" cohort of patients was therefore not only to attributable a lack of predictive biomarkers, but also to treatment of patients with a too short life span.
In conclusion, we show that treatment with anti-PD-1 antibodies may induce an immunological imprint of T-and B-cell antigenic selection in the blood of cancer patients. Prospective studies will have to show whether this signaturealong with genetic and molecular tumor profiling -will provide a basis for personalized, potentially more effective and selective immunotherapy. In addition, our data clearly discourages PD-1 directed immunotherapy in patients with an estimated life expectancy of less than 2-3 months. 
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